136 related articles for article (PubMed ID: 23963362)
1. Molecular radiotherapy using cleavable radioimmunoconjugates that target EGFR and γH2AX.
Cornelissen B; Waller A; Able S; Vallis KA
Mol Cancer Ther; 2013 Nov; 12(11):2472-82. PubMed ID: 23963362
[TBL] [Abstract][Full Text] [Related]
2. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
3. Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical.
Cornelissen B; Darbar S; Kersemans V; Allen D; Falzone N; Barbeau J; Smart S; Vallis KA
Nucl Med Biol; 2012 Nov; 39(8):1142-51. PubMed ID: 22819196
[TBL] [Abstract][Full Text] [Related]
4. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
[TBL] [Abstract][Full Text] [Related]
5. PET imaging of DNA damage using (89)Zr-labelled anti-γH2AX-TAT immunoconjugates.
Knight JC; Topping C; Mosley M; Kersemans V; Falzone N; Fernández-Varea JM; Cornelissen B
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1707-1717. PubMed ID: 26031435
[TBL] [Abstract][Full Text] [Related]
6. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.
Panosa C; Fonge H; Ferrer-Batallé M; Menéndez JA; Massaguer A; De Llorens R; Reilly RM
Nucl Med Biol; 2015 Dec; 42(12):931-8. PubMed ID: 26385534
[TBL] [Abstract][Full Text] [Related]
7. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
Costantini DL; Chan C; Cai Z; Vallis KA; Reilly RM
J Nucl Med; 2007 Aug; 48(8):1357-68. PubMed ID: 17631548
[TBL] [Abstract][Full Text] [Related]
8. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
9. Imaging DNA damage in vivo using gammaH2AX-targeted immunoconjugates.
Cornelissen B; Kersemans V; Darbar S; Thompson J; Shah K; Sleeth K; Hill MA; Vallis KA
Cancer Res; 2011 Jul; 71(13):4539-49. PubMed ID: 21586614
[TBL] [Abstract][Full Text] [Related]
10. Panitumumab-DOTA-
Facca VJ; Cai Z; Gopal NEK; Reilly RM
Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
[TBL] [Abstract][Full Text] [Related]
11. 111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1.
Cornelissen B; Kersemans V; McLarty K; Tran L; Reilly RM
Cancer Biother Radiopharm; 2009 Apr; 24(2):163-73. PubMed ID: 19409037
[TBL] [Abstract][Full Text] [Related]
12. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225.
Wen X; Wu QP; Ke S; Ellis L; Charnsangavej C; Delpassand AS; Wallace S; Li C
J Nucl Med; 2001 Oct; 42(10):1530-7. PubMed ID: 11585869
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
Chan C; Fonge H; Lam K; Reilly RM
Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
[TBL] [Abstract][Full Text] [Related]
14. EGF-coated gold nanoparticles provide an efficient nano-scale delivery system for the molecular radiotherapy of EGFR-positive cancer.
Song L; Falzone N; Vallis KA
Int J Radiat Biol; 2016 Nov; 92(11):716-723. PubMed ID: 26999580
[TBL] [Abstract][Full Text] [Related]
15.
Kwon LY; Scollard DA; Reilly RM
Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
[TBL] [Abstract][Full Text] [Related]
16. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates.
Razumienko E; Dryden L; Scollard D; Reilly RM
Breast Cancer Res Treat; 2013 Apr; 138(3):709-18. PubMed ID: 23525982
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
Bailey KE; Costantini DL; Cai Z; Scollard DA; Chen Z; Reilly RM; Vallis KA
J Nucl Med; 2007 Sep; 48(9):1562-70. PubMed ID: 17704253
[TBL] [Abstract][Full Text] [Related]
18. Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy.
Terry SY; Vallis KA
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1298-305. PubMed ID: 22336201
[TBL] [Abstract][Full Text] [Related]
19. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
[TBL] [Abstract][Full Text] [Related]
20. ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
Cornelissen B; Darbar S; Hernandez R; Kersemans V; Tullis I; Barber PR; Smart S; Vojnovic B; Reilly R; Vallis KA
J Nucl Med; 2011 May; 52(5):776-83. PubMed ID: 21498540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
